Approximately 108,192 bottles and blister packs of Abilify (aripiprazole) tablets have been voluntarily recalled by Otsuka Pharmaceutical. The recall includes 5 mg, 10 mg, 15 mg, and 30 mg tablets that may have been cross-contaminated with other products during manufacturing at the Second Tokushima Factory in Japan. Consumers are advised to contact their healthcare provider or pharmacist regarding their medication and return any affected products to the place of purchase for a refund.
The tablets may have been cross-contaminated with other pharmaceutical products during the production process. This poses a risk that patients could be exposed to unintended substances, which could lead to adverse health effects or reduce the efficacy of their treatment.
You have 2 options:
RX only
RX only
RX only
RX only
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.